The CIC-backed eye disease treatment developer has filed for a $100m initial public offering, having raised over $250m in funding in the past two years.

Gyroscope Therapeutics, a UK-based developer of treatments for retinal diseases co-founded by University of Cambridge and Syncona, has filed for an initial public offering in the United States. The company has set a placeholder target of $100m and intends to float on the Nasdaq Global Select Market. Gyroscope is developing gene therapies for the treatment…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.